OR WAIT null SECS
© 2023 MJH Life Sciences™ and Rheumatology Network. All rights reserved.
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending October 1, 2021.
Test your knowledge of the treatment and management of rheumatoid arthritis (RA) with our RA quizzes.
Click the image to view the story.
“Understanding the role of ixekizumab will allow physicians to translate a higher Assessment of Spondyloarthritis International Society (ASAS) achievement to the improvements in the signs and symptoms reported by their patients,” investigators stated.
Click the image to view the story.
More patients with methotrexate intolerance receiving baricitinib 4 mg and adalimumab had no progression in radiographic progression at year 5 when compared with placebo.
Click the image to view the story.
“Considering the fact that people with one and the same clinical condition can vary substantially in terms of disability, there is a need to expand the assessment tools,” investigators stated.
Click the image to view the story.
While telemedicine is a valuable tool to provide access to care for families seeking care within a small subspecialty with a limited supply of providers, there was a significantly lower amount of new pediatric patient visits in the beginning of the COVID-19 pandemic.
Click the image to view the story.